Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 5
2021 4
2022 4
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Long term update on toxicity and survival of a phase II trial of linac-based stereotactic body radiation therapy for low-intermediate risk prostate cancer.
D'Agostino GR, Badalamenti M, Stefanini S, Baldaccini D, Franzese C, Faro LL, Di Cristina L, Vernier V, Reggiori G, Scorsetti M. D'Agostino GR, et al. Among authors: badalamenti m. Prostate. 2024 Mar;84(4):368-375. doi: 10.1002/pros.24657. Epub 2023 Dec 19. Prostate. 2024. PMID: 38112222 Clinical Trial.
Toxicity profile and Patient-Reported outcomes following salvage Stereotactic Ablative Radiation Therapy to the prostate Bed: The POPART multicentric prospective study.
Ferrario F, Franzese C, Faccenda V, Vukcaj S, Belmonte M, Lucchini R, Baldaccini D, Badalamenti M, Andreoli S, Panizza D, Magli A, Scorsetti M, Arcangeli S. Ferrario F, et al. Among authors: badalamenti m. Clin Transl Radiat Oncol. 2023 Nov 25;44:100704. doi: 10.1016/j.ctro.2023.100704. eCollection 2024 Jan. Clin Transl Radiat Oncol. 2023. PMID: 38111610 Free PMC article.
Adaptive Volumetric-Modulated Arc Radiation Therapy for Head and Neck Cancer: Evaluation of Benefit on Target Coverage and Sparing of Organs at Risk.
Franzese C, Tomatis S, Bianchi SP, Pelizzoli M, Teriaca MA, Badalamenti M, Comito T, Clerici E, Franceschini D, Navarria P, Di Cristina L, Dei D, Galdieri C, Reggiori G, Mancosu P, Scorsetti M. Franzese C, et al. Among authors: badalamenti m. Curr Oncol. 2023 Mar 13;30(3):3344-3354. doi: 10.3390/curroncol30030254. Curr Oncol. 2023. PMID: 36975467 Free PMC article.
Multimodal Treatments for Brain Metastases from Renal Cell Carcinoma: Results of a Multicentric Retrospective Study.
Navarria P, Pessina F, Minniti G, Franzese C, Marini B, D'agostino G, Badalamenti M, Raspagliesi L, Reggiori G, Lobefalo F, Fariselli L, Franceschini D, Bellu L, Clerici E, Pinzi V, Scorsetti M. Navarria P, et al. Among authors: badalamenti m. Cancers (Basel). 2023 Feb 22;15(5):1393. doi: 10.3390/cancers15051393. Cancers (Basel). 2023. PMID: 36900186 Free PMC article.
Predictive value of clinical and radiomic features for radiation therapy response in patients with lymph node-positive head and neck cancer.
Franzese C, Lillo S, Cozzi L, Teriaca MA, Badalamenti M, Di Cristina L, Vernier V, Stefanini S, Dei D, Pergolizzi S, De Virgilio A, Mercante G, Spriano G, Mancosu P, Tomatis S, Scorsetti M. Franzese C, et al. Among authors: badalamenti m. Head Neck. 2023 May;45(5):1184-1193. doi: 10.1002/hed.27332. Epub 2023 Feb 23. Head Neck. 2023. PMID: 36815619
Stereotactic Radiotherapy after Incomplete Transarterial (Chemo-) Embolization (TAE\TACE) versus Exclusive TAE or TACE for Treatment of Inoperable HCC: A Phase III Trial (NCT02323360).
Comito T, Loi M, Franzese C, Clerici E, Franceschini D, Badalamenti M, Teriaca MA, Rimassa L, Pedicini V, Poretti D, Solbiati LA, Torzilli G, Ceriani R, Lleo A, Aghemo A, Santoro A, Scorsetti M. Comito T, et al. Among authors: badalamenti m. Curr Oncol. 2022 Nov 16;29(11):8802-8813. doi: 10.3390/curroncol29110692. Curr Oncol. 2022. PMID: 36421345 Free PMC article. Clinical Trial.
The impact of stereotactic ablative radiotherapy on oligoprogressive metastases from renal cell carcinoma.
Franzese C, Marini B, Baldaccini D, Badalamenti M, Navarria P, Bellu L, Franceschini D, Comito T, Clerici E, Teriaca MA, Massaro M, Di Cristina L, Lo Faro L, Tomatis S, Scorsetti M. Franzese C, et al. Among authors: badalamenti m. J Cancer Res Clin Oncol. 2023 Jul;149(8):4411-4417. doi: 10.1007/s00432-022-04352-z. Epub 2022 Sep 15. J Cancer Res Clin Oncol. 2023. PMID: 36109401
Oligoprogressive castration-resistant prostate cancer treated with metastases-directed stereotactic body radiation therapy: predictive factors for patients' selection.
Franzese C, Perrino M, Marzo MA, Badalamenti M, Baldaccini D, D'Agostino G, Marini B, De Vincenzo F, Zucali PA, Scorsetti M. Franzese C, et al. Among authors: badalamenti m. Clin Exp Metastasis. 2022 Jun;39(3):449-457. doi: 10.1007/s10585-022-10158-7. Epub 2022 Feb 21. Clin Exp Metastasis. 2022. PMID: 35190933
18 results